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Abstract 
Objective: Lepidium meyenii (Maca), a herbaceous plant, has been used for centuries for its 
fertility enhancing and aphrodisiac properties. In an Australian study, Maca improved anxiety 
and depressive scores. The effects of Maca on hormones, lipids, glucose, serum cytokines, 
blood pressure, menopausal symptoms and general well-being in Chinese postmenopausal 
women were evaluated  
Methods: A randomized, double-blind, placebo-controlled crossover study was conducted in 
29 postmenopausal Hong Kong Chinese women. They received 3.3 g/day of Maca or placebo 
for 6 weeks each, in either order, over 12 weeks. At baseline, week 6 and week 12, estradiol, 
follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), thyroid stimulating 
hormone (TSH), full lipid profiles, glucose and serum cytokines, were measured. The Greene 
Climacteric, SF-36v2, Women’s Health Questionnaire and Utian quality of life, scales were 
used to assess the severity of menopausal symptoms and health related quality of life.  
Results: There were no differences in estradiol, FSH, TSH, SHBG, glucose, lipid profiles and 
serum cytokines amongst those who received Maca as compared to placebo group, however, 
a significant decrease in both systolic and diastolic blood pressure was apparent after Maca 
treatment. The Greene Climacteric Scale revealed lower scores in the areas of psychological 
symptoms, including anxiety and depression following Maca. SF-36v2 showed stronger 
improvement in general and mental health when compared to baseline, whilst the women’s 
health questionnaire showed improvement in depression and anxiety symptoms following 
Maca consumption. The Utian quality of life scoring did not show any differences in all domains 
tested. 
Conclusions: Maca does not exert hormonal or immune biological action in the small cohort of 
patients studies, however, it appears to reduce symptoms of depression and improve diastolic 
blood pressure in Chinese postmenopausal women. Although results are comparable to 
previous similar published studies in postmenopausal women, there might be a cultural 
difference among the Chinese postmenopausal women in terms of symptom reporting.  
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INTRODUCTION 
Hormone replacement therapy (HRT) is the most effective treatment for the relief of 
menopause symptoms, yet many women have become reluctant to continue or commence 
HRT due fear of adverse risks1.  Instead women seek alternative treatment options, particularly 
complementary and alternative therapies2.  A study conducted in Australian women revealed 
over 50% of respondents had used complementary and alternative medicines or had visited a 
practitioner for the alleviation of menopausal symptoms. Further, following the release of the 
Women’s Health Initiative Study indicating that HRT was associated with adverse health risks3, 
there has been an increase in the number of dietary supplements manufactured specifically 
targeting menopausal women4. 
Numerous alternative therapies currently available claim to provide a wide array of 
benefits to menopausal women, of which some, including soy and black cohosh, have been 
supported by scientific evidence4. There are, however, numerous products for which benefit 
has been claimed although scientific support is lacking2. Maca is one example. Maca is a 
herbaceous biennial plant, the root of the plant Lepidium meyenii, is grown exclusively at high 
altitude (3,800-4,400 m above sea level) in the Andes region of Peru and Bolivia, where it is 
widely used for its putative fertility enhancing and aphrodisiac properties5. 
Maca is marketed commercially for its reported benefit in relieving menopause 
symptoms, although there is scant published scientific data to support any efficacy6. Initial 
research has focussed on a possible role for Maca in improving male fertility7-14 with emerging 
evidence that Maca may improve sperm production and quality7. Although few studies have as 
yet examined the effect of Maca in women, data from oophorectomized rats, suggests that 
Maca can improve bone mass and restore trabecular network in the lumbar vertebrae, findings 
relevant to the high risk of osteoporosis many women face after menopause15. 
The mechanisms by which Maca may affect the male or female reproductive system 
remain to be elucidated. The possibility of estrogenic effects is based on the fact that Maca 
contains the phytoestrogen β-sitosterol13.  Several studies, however have been unable to 
detect in vivo estrogenic effects9,10,13, although one study has reported that Maca extracts 
promote proliferation of MCF-7 cells, an estrogen receptor positive human breast cancer cell 
line16.  Alkaloids, isothiocynates and glucosinolates are also potential active constituents of 
Maca15.  One constituent, namely the glucosinolate indoly-3-methyl (glucobrassicin) may 
modulate androgenic activity as it can be enzymatically hydrolysed to 3,3-diindolylmethane 
(DIM), known as a specific antagonist of the androgen receptor17,18. To our knowledge, DIM is 
the first example of a pure androgen receptor antagonist from plants18. 
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This study seeks to examine the effect of Lepidium Meyenii (Maca) on hormonal profile 
and symptoms in Chinese (Hong Kong) postmenopausal women. In a randomized cross-over 
design study, serum sex hormone levels, TSH, SHBG, glucose, cytokines, and, lipid 
concentrations were measured in 29 post-menopausal women. Furthermore, as women often 
report that Maca is beneficial in alleviating menopause symptoms, changes in menopausal 
symptoms have also been examined in our study using the Greene Climacteric Scale, SF-
36v2, the Women’s Health Scale and the Utian Quality of Life Scale, all well-validated 
questionnaires. Although a similar methodology as described in this study has been used 
previously in Caucasian post-menopausal women19, to our knowledge this is the first study 
examining the effects of Maca in a small cohort (pilot study) of Chinese women from Hong 
Kong which is a different cultural and ethnic group. 
 
 
METHODS 
 
Subjects 
Thirty four healthy postmenopausal women aged between 46-59 years, who were 
currently experiencing symptoms of menopause, recruited by newspaper advertisement, 
participated in this study. All women were amenorrheic for 12 months or longer. Subjects were 
excluded from the study if they were currently on HRT or had taken HRT within the last 6 
months; if they had a cardiac, renal, hepatic, inflammatory or psychiatric condition, or if they 
regularly consumed more than two standard alcoholic drinks each day. Subjects were also 
excluded if they currently consumed Maca supplements, or other Chinese or alternative 
medicine supplements for the relief of menopause symptoms. Subjects were required not to 
consume any dietary supplements or Chinese herbal therapies for the duration of the study. 
 
Study Design 
The study protocol was approved by the Clinical Research Ethics Committee of the 
Chinese University of Hong Kong and written informed consent was obtained from all 
participants. This was a 12 week randomized, single centre, double-blinded, placebo-controlled 
crossover trial. A completely randomized factorial design method was used and a researcher 
not involved with the study kept the study staff blinded to participants' treatment order. The 
sample size for this study was based on previous results published by the principal 
investigator27. Twenty-nine out of 34 women completed the trial. Fifteen women commenced 
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the Maca treatment first and 14 women commenced the placebo treatment first. Each subject 
received 3.3 g/day Maca or placebo in identical appearance and packed identically in 
capsulated form, for 6 weeks, in random order, with the entire study extending over a period of 
12 weeks. The recommended and safe dose of Maca is up to 4 g daily. Women in this study 
will be consuming 3.3 g/day which is just below or equivalent to the daily recommended dose 
on the package of our supplier, and is based on previous human studies8,9,19  At baseline, week 
6 and week 12, venous blood samples were collected for the measurement of serum estradiol, 
FSH, SHBG, TSH, full lipid profiles, glucose and serum cytokines. At baseline, week 6 and 
week 12, women also completed the Greene Climacteric Scale (GCS) and SF-36 Version 2, 
quality of life questionaries to determine whether there had been any change in the severity of 
their physiological and psychological symptoms as well as changes in quality of life. A 
determination of height, body weight and blood pressure was also taken at these three time 
points. Maca is a root of the plant Lepidium meyenii cultivated high in the Andean Mountains 
and comes prepared to us in capsulated form (Maca Power, Healthychoices, Murwillumbah 
NSW, Australia), with each capsule containing 462 mg net Maca. Maca root also contains 
amino acids, complex carbohydrates, vitamins B1, B2, C, E and minerals. A placebo of 
matching color and consistency (refined white rice flour) was provided in an identical dose and 
packaging. Subjects were asked to consume one 3.3 g dose consisting of 7 capsules of Maca 
or placebo per day, 4 capsules following breakfast and 3 following dinner to ensure uniform 
concentration throughout the 24 hour cycle. For convenience, a daily and weekly dose was 
packed in plastic sachets. Participants' compliance with treatment was monitored. They were 
required to bring in any unused capsules at the next scheduled visit. 
  
Measurements 
Serum estradiol (E2), FSH, SHBG, TSH and lipids were analyzed by the pathology 
laboratory (Prince of Wales Hospital, New Territory, Hong Kong). Serum E2, FSH and TSH 
were analyzed using the Roche E170 immunoassay analyser with ECLIA technology (Roche 
Diagnostics, Indianapolis IN, USA). Mean intra-assay and inter-assay coefficient variations for 
the TSH assay were 1.2% and 4.0%, for the E2 assay were 1.6% and 6.4% and for the FSH 
assay were 1.7% and 4.4% respectively. 
SHBG was determined using a solid-phase chemiluminescent immunometric assay 
measured on the Immulite 1000 SHBG immunoassay system (Simens Medical Solution 
Diagnostics Diagnostic, Los Angeles, CA, USA). Mean Intra-assay and inter-assay coefficient 
variations for the SHBG assay were 4.5% and 5.7% respectively.  
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Serum lipids were measured using calorimetric test using DP Modular Analytics with 
mean Intra-assay and inter-assay coefficient variations for cholesterol and HDL assays were 
1.7% and 1.9% respectively, while for TG Intra-assay and inter-assay coefficient variations 
were 1.2% and 2.8% respectively. 
Cytokines (IL-2, IL-4, IL-5, IL-10, IL-12 (p70), IL-13, GM-CSF, IFN-γ and TNF-α), were 
detected simultaneously in plasma samples using a multiplex pre-mixed human cytokine 
Th1/Th2 assay (Bio Rad, VIC Australia) according to the manufacturer’s instructions. Briefly, 
serial dilutions of the reconstituted premixed standards were performed using standard diluent, 
resulting in a standard curve.  Samples were also diluted 1:4 in appropriate diluent. Standards 
and samples were subsequently incubated in 96-well plates with anti-human antibody-coated 
beads provided.  Removal of unbound protein was facilitated by a series of three washes using 
the Bio-plex vacuum manifold system and wash buffer.  Biotinylated secondary and 
streptavidin-phycoerythrin antibodies were then sequentially bound to the beads to enable 
cytokine detection.  Finally, the assay plates were loaded into a Bio-plex array reader to detect 
bound cytokines, and data analysed using the Bio-plex manager software. 
Plasma glucose measurements were conducted at Victoria University’s sports 
performance laboratory, Footscray Park, Melbourne, using a YSI 2300 STAT plus glucose 
analyzer (YSI).  Frozen samples were thawed and vortexed to resuspend components prior to 
presenting each sample to the YSI sipper arm. The YSI ran an automatic calibration after every 
ten samples. Plasma glucose definitions were based on WHO diagnostic criteria (2006), 
namely Diabetes as fasting plasma glucose of ≥7.0mmol/l, and Impaired Fasting Glucose (IFG) 
as fasting plasma glucose of 6.1 to 6.9mmol/l. 
The GCS is a well validated, non-intrusive self report questionnaire which measures the 
physical and psychological symptoms associated with menopause. The scale assesses 
psychological symptoms, with sub-scales for anxiety and depression, somatic symptoms, 
vasomotor symptoms, and sexual dysfunction. A total score is also calculated20. Test reliability 
for the subscales ranges from 0.83 for the vasomotor scale to 0.87 for the psychological 
scale20,21. 
The SF-36 Health Survey developed by Ware et al and subsequently modified (SF-
36v2) by the same authors in 199622, is the most widely used health-related quality of life 
(HRQOL) measures worldwide, including Hong Kong, with over 4,000 publications23. The 
survey includes 36 items summarized into eight multi-item scales, along with 1 item of health 
change: physical functioning, role physical, bodily pain, general health, vitality, social 
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functioning, role emotional and mental health23,24. SF-36 has been translated and validated in 
more than 22 countries, including for the Chinese population in Hong Kong. Reliability 
estimates for physical and mental summary scores usually exceed 0.9025. Test reliability for the 
subscales is more than 0.80 (with 0.93 for mental health), except for social functioning, which 
has a median reliability of 0.7625.  
The Women’s Health Questionnaire (WHQ) was developed in the 1980s by Myra 
Hunter at London University26. The WHQ contains 36 questions assessing 9 domains of mental 
and physical health, rated on a 4-point scale and was developed specifically for women during 
menopause transition and is available in 27 languages. WHQ measures the following 
subclasses, depressed mood, somatic symptoms, sleep problems, anxiety/fears, sexual 
behaviour, vasomotor symptoms, menstrual symptoms, memory/concentration and 
attractiveness. Test reliability ranges from 0.78 to 0.96 suggesting that WHQ is a highly reliable 
measure for mid-aged women’s emotional and physical health27. 
The Utian Quality of Life (UQOL) Questionnaire is a quick 2 page (5 minute), 23 item, 
validated questionnaire that clinicians use, for clinical or research purposes, to understand a 
woman’s menopause-related quality of life28. The UQOL Scale assesses occupational, health, 
emotional, and sexual quality of life and the test reliability ranges from 0.88-0.9129. 
 
Statistical analysis 
Statistical analyses were performed using SPSS (version 16.0, SPSS Inc. Chicago).  All 
data is expressed as the mean ± SD. Data were first assessed for normality using the Kurtosis 
test. Analyses of hormone levels, GCS, SF-36V2 and body weight were performed using one 
way repeated measures analysis of variance (ANOVA) with Tukey significance difference as a 
post hoc analysis account for paired data. A P value of < 0.05 was considered of statistical 
significance. One-way ANOVA analyses using treatment order as a between subjects factor 
indicated that there was no carryover effect in any of the measured variables.  
 
 
 
RESULTS 
Study population 
Seventy-five women responded to an advertisement in a local Chinese newspaper. 
Following initial telephone screening 34 women were recruited, out of which 29 women 
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completed the trial. Five participants dropped out of the study within the first 4 weeks of 
commencement, 1 woman went on prolonged overseas trip, 2 became disinterested in the 
study, whilst 2 women dropped out due to time constrains. Data have therefore been analysed 
for a total of 29 women only, and the study is considered a small pilot study. 
At the commencement of the study, the mean age of participants was 52.4±2.7 years 
(mean ± SD); had median duration of amenorrhoea 26.4±11.2 months and mean body mass 
index (BMI) of 23.2±3.1 kg/m2. It is generally accepted that BMI between 18.5-25 is normal 
healthy weight, with 25-30 being overweight and BMI above 30 being obese, in the western 
world. However, there are international variations, set by the World Health Organization 
guidelines and in the Asian population the healthy BMI range is 18.5-22.9, with 23-24.9 being 
overweight and above 25 to be considered obese. Hence a proportion of the subjects were in 
the overweight and obese range. During the study, both body weight and BMI did not change 
significantly (Table 1).   
 
Hormone profile 
Anthropometric measures, serum hormone levels of estradiol, FSH, SHBG, TSH and 
lipid profile were measured at baseline, 6 and 12 weeks (Table 2). Spatial decrease in systolic 
(P = 0.05) and diastolic (P = 0.01) blood pressure were detected after 6 weeks of Maca which 
were statistically significant over baseline levels (Table 2). However, systolic decrease was 
also noted in placebo group, which as significant compared to baseline levels. No statistically 
significant changes in serum hormone levels or SHBG were noted (P > 0.05). Post hoc 
analysis however, show, that our study is only powered to detect a significance at (P = 0.8 and 
lambda = 0.05) a 15% increase in estradiol. 
 
Physiological measurements 
 The Th1 and Th2 cytokines, the main cytokines involved in humoral and cellular 
immunity, were assessed to determine whether Maca intake had an effect physiologically (at 
the cellular level). Three cytokines (IL-5, IL-10 and IL-13) were detectable within range at the 
lower end, whilst 6 cytokine measures (IL-2, IL-4, IL-12, GM-CSF, IFN-γ, TNF-α) were found to 
be in concentrations beyond detectable range (OOR<). For analysis purposes, OOR< 
(undetectable) readings were included in calculations as zero values. Our results indicate that 
there was minimal variation in detectable cytokines between time 0, the placebo and Maca 
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supplemented groups and these variations were not statistically significant when applied to the 
Student t-test (data not shown).  
 The mean fasting plasma glucose for this cohort was slightly elevated in both placebo 
and Maca treatments when compared to values at Time 0, but this was negligible and not 
statistically significant (data not shown). At Time 0, 2/27 patients had impaired fasting glucose 
levels as defined by WHO (2006). The fasting plasma glucose for these patients decreased 
with placebo as well as with Maca treatment, however these changes were not statistically 
significant (data not shown), the study group is too small, and other factors apart from impaired 
glucose tolerance may have contributed to elevated plasma glucose at Time 0 in those 
subjects.  Similar studies in a larger cohort with known impaired glucose tolerance may be 
warranted as to Maca’s effect on plasma glucose. 
 
Greene climacteric scale 
The Greene climacteric scale (GCS) is shown in Table 3. The psychological scale 
indicated that Maca treatment was associated with a significant reduction in symptom scores 
(30% reduction from baseline values, P < 0.05) and after treatment with placebo (27% less 
than after placebo, P < 0.05). The psychological scale contained two subgroups, anxiety and 
depression.  Results for the anxiety scale show a significant reduction in scores following Maca 
treatment compared to baseline, (30.8% reduction, P < 0.05) and values after treatment with 
placebo (27.3% decrease, P < 0.05). The second subscale measured depression where again 
a significant reduction in scores was seen following Maca in comparison to either baseline or 
after placebo (28.9% and 26.8%, respectively, both P < 0.05). In addition, somatic symptoms 
were significantly decreased by 27% (P < 0.05) compared to baseline. 
The GCS also allows for a total score to be calculated. Maca decreased total scores by 
22.5% in comparison to baseline (P = 0.07), however, a significant reduction was noted in the 
placebo group with a 26% reduction (P < 0.04). There were no significant changes seen in 
sexual dysfunction, vasomotor and urinary scores over the trial. 
 
SF-36v2 scale 
The mental and physical health of all participating subjects were assessed. Following 
Maca, patients clearly reported a significant increase in their overall health functioning, in 
particular, general wellbeing (10.8% increase, P < 0.05) and mental health (13.5% increase, P 
< 0.05) (Table 4), however, similar increases were noted following placebo. Following placebo, 
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social functioning (16.4% increase, P < 0.05), and the mental component score (13% increase, 
P < 0.05) were significantly increased to baseline. There were no statistical differences in 
physical functioning, role physical, body pain, vitality, role emotional and in the physical 
component score (Table 4). 
 
 
Women’s Health Questionnaire Scale 
Nine domains of mental and physical health of all participating subjects were assessed. 
Following Maca, patients clearly reported statistically significant (34 - 36 %, P < 0.05) 
decreases in, depression and anxiety/fears. Similarly placebo showed significant decrease in 
anxiety score, as well as somatic symptoms and sleep problems (Table 5). No differences 
were reported for memory, vasomotor, sexual dysfunction, mental, and, attention states (Table 
5). Interestingly, in the Greene scale and in the WHQ scale, sexual dysfunction showed non 
significant improvement in both Maca and placebo, even though there we’ve noted a significant 
improvement in a similar study in a Caucasian population19. 
 
 
Utian Quality of Life (UQOL) Questionnaire 
The UQOL questionnaire in all 4 domains of occupational, health, emotional and sexual 
quality of life showed no statistical difference following Maca intake (Table 6). 
 
 
DISCUSSION 
 Following the publication in 2002 of the first Women’s Health Initiative (WHI) report30, a 
dramatic decrease in HRT use resulted world-wide, mainly due to the fear of increased risk of 
developing breast cancer31. As a consequence, a large proportion of women seek alternative 
and complementary strategies for relief of menopausal symptoms, even though they are not as 
effective as HRT in treating the climacteric symptoms.  
Maca has been used for centuries in the Andes to manage anaemia, infertility and 
hormonal balances in women. However, this is based on the long history of traditional usage 
and anecdotal information by local population groups. Recently, much interest on the 
properties of Maca has resulted in research leading to evidence of its medicinal effects in 
animals and in humans. In mouse and rat studies, Maca has been shown to be effective in the 
prevention of estrogen deficient bone loss, improves glucose tolerance, improves memory 
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impairment, improves sexual behaviour, invigorates spermatogenesis, exerts anti-hyperplastic 
effects on the prostate, and, increases litter size in female mice14,15,32-34. In bulls, Maca 
supplementation improved sperm quantity and quality whilst mating behaviours were 
unaffected35. Likewise, in human studies Maca is associated with, improved semen 
parameters7, improved sexual desire in men9 with no relationship to testosterone levels8, 
helpful for erectile dysfunction36, and improves symptoms of female sexual dysfunction37. Maca 
has also been noted to increase testosterone levels in females regularly consuming Maca38. 
We previously reported, in 14 postmenopausal women in a randomized, double-blind placebo-
controlled crossover trial, that Maca had beneficial effects on psychological symptoms and 
measures of sexual dysfunction, but were not related to estrogen or androgen levels27. In other 
randomized clinical trials supplementation of Maca in pre- peri- and post-menopausal women 
showed favourable outcomes based on Kupperman Menopausal index and the Greene 
Climacteric Score (GCS). Furthermore, limited studies have shown evidence for Maca’s effect 
on blood markers. Serum IL-6 levels in a cross-sectional study in 50 subjects was measured 
with, 27 subjects consuming Maca and 23 did not consuming Maca. IL-6 was lower in the 
Maca group and overall better health status scores in the SF-20 survey39. 
This study set out to determine the effect of consuming Maca for 6 weeks in Chinese 
postmenopausal women from Hong Kong. It is clear that there were no differences in weight, 
BMI, heart rate, estradiol, FSH, SHBG, TSH, HDL, LDL, triglycerides, plasma cytokines and 
glucose amongst the Maca and placebo groups, however, there were significant decreases in 
both systolic and diastolic blood pressure following Maca intake, with diastolic blood pressure 
being highly significant above baseline and compared to placebo group. As blood pressure is a 
risk factor for cardiovascular disease, this could potentially be a significant finding for lowering 
cardiovascular disease risk. Previous studies had also demonstrated that Maca had no effects 
on serum estradiol, FSH and TSH levels9 despite other reports suggesting that Maca elevates 
LH and reduced FSH following Maca supplemention6.  
Maintaining optimal quality of life is a priority for women just before, during and post 
menopause. Measuring quality of life has traditionally been via medicines and biomedical 
measurements that determine the health status, however, these are not sufficient to accurately 
determine the overall well-being. Therefore, quality of life scales have been developed with the 
main objectives in mind, being, psychometric and physical properties. The Greene Climacteric 
Scale (GCS) measures psychological, somatic and vasomotor symptoms. The Scale is used to 
determine changes of symptoms in response to treatment interventions20,21. Herein, Chinese 
post menopausal women after Maca supplementation was associated with significant reduction 
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in psychological (anxiety and depression) and somatic symptom scores, even though similar 
changes were observed following placebo supplementation. Maca showed non significant 
decrease in sexual dysfunction, vasomotor and urinary scores. 
The SF-36v2 health survey assesses functional health (mental and physical) and well 
being22. The scale determines improvement or decline in health and treatment effectiveness22-
24. In the current study, following Maca supplementation in Chinese post menopausal women, 
subjects showed significant improvement in general and mental health with non-significant 
improvement in body pain, vitality, social functions and mental component scores. Interestingly, 
placebo show similar trends to Maca, with significant improvement in social functioning and 
mental component scores. 
The Women’s Health Questionnaire (WHQ), a 36 item questionnaire covering 9 areas 
of physical and mental status, is a well accepted international questionnaire in assessing post-
menopausal symptoms. In Chinese postmenopausal women after Maca supplementation, a 
significant improvement in depression scores and anxiety scores were noted, with non-
significant decrease in somatic, memory, vasomotor, sexual dysfunction, mental and attention 
scores. However, placebo showed significant improvements in somatic, anxiety and sleep 
scores but not in the depression score. Using the Utian Quality of Life (UQOL) score, there 
were no statistically significant differences in all 4 domains of occupational, health, emotional 
and sexual quality of life. In the recently translated but not validated Chinese UQOL 
demonstrated varied test reliabilities, with 0.86 (overall), 0.85 (occupational), 0.7 (health 
related), 0.66 (emotional) and 0.61 (sexual)29. The low reliability scores for emotional and 
sexual suggest that the reliability for these 2 domains requires further studies. Hence, the 
inconsistent result of UQOL in the current study compared to GCS, Sc-36v2 and WHQ 
surveys. It is clear from GCS, Sc-36v2 and WHQ surveys, that postmenopausal Chinese 
woman taking Maca supplements, resulted in significant improvement diastolic blood pressure 
and depression scores. This is an important outcome given that post-menopausal women are 
3-times more likely to report symptoms of depression compared to pre-menopausal women. 
Furthermore postmenopausal women are more likely to present with cardiovascular disease as 
compared to men at the same age group. The studies are in accord to previous studies in 
males treated with Maca for 12 weeks which lowered depression scores9, in post menopausal 
women treated with Maca showed improved anxiety and depressive scores19, and 
demonstrated anti-depressant actions in mice40. It is not clear how Maca acts on reducing 
psychological symptoms, although flavonoids present in Maca may be responsible for these 
actions40-43. Interestingly, the reduced psychological symptoms (depression and anxiety) did 
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not correlate with reduced vasomotor symptoms (hot flushes), despite a strong association 
between the two44,45. However, estradiol, FSH and TSH levels are associated with vasomotor 
symptoms, and no changes were noted in these hormones together with no improvement of 
vasomotor symptoms46. However, sleep disorders were significantly improved. Similar findings 
of no beneficial effects of vasomotor symptoms in Hong Kong Chinese post menopausal 
women were reported with the Chinese herb Dang Gui Buxue Tang47. In the current study, 
there was improvement but not significant in sexual dysfunction (commonly reported in 
menopausal women), despite previous studies of Maca supplementation in post menopausal 
Australian women19, in men9 and in rodents14. There are suggestions that women in non-
Western countries do not usually report their sexual functions and mental states, but rather 
freely report somatic symptoms such as headache, back pain and constipation, as opposed to 
women in Western or developed countries48-50. Various studies indicate that differences in 
symptom reporting are real and that both biological variation and cultural differences contribute 
to the menopausal transition and that more research is required to elucidate how biology and 
culture interact in female ageing51,52. 
 
 
CONCLUSIONS 
Overall, we demonstrate that Maca does not exert an estrogenic effect in 
postmenopausal Hong Kong Chinese women, as indicated by the lack of change in plasma 
estradiol, FSH, TSH and SHBG concentrations. In addition, Maca has no effect, in immune 
physiology or other biological markers, in the short term, on body weight, BMI, cholesterol, 
HDL, LDL, triglyceride, glucose and cytokine levels. However, Maca was shown in the small 
cohort of patients, to be effective in reducing blood pressure and depression. Improvements 
were also noted for psychological, anxiety, somatic, general health, social functioning and 
mental health in both Maca and placebo groups. Although these results are comparable to 
previous similar published studies in postmenopausal women from our and other laboratories. 
In general, there might be cultural differences amongst the Chinese postmenopausal women in 
terms of symptom experiencing and reporting, as compared to the Caucasian population. In 
fact, it has been reported that although the incidence of hot flushes, for example, among the 
western women are close to 80%, only 5 - 10 % of the Asian women report troublesome 
vasomotor symptoms53. These differences may be due to both cultural and biological 
variations51, however, diet may account for some of it.  Although there have been a number of 
observational and randomized controlled trials conducted for relief of menopausal symptoms, 
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especially vasomotor, the clinical evidence supporting the efficacy and safety of most 
Complementary medicine for relief of menopausal symptoms is sparse. Differences in findings 
across studies of the same product may be due to less than optimal trial design, variation in 
products and composition of products used, inadequate dosing, the length of treatment and 
small population size. Furthermore, any therapy claiming to reduce hot flushes should be 
assessed in blinded trials as placebo effects are high54. Furthermore, the placebo effect In our 
studies were high demonstrating the person’s anticipation that an intervention will help them, 
and these effects should be considered in alternative therapies55. This study gives strong 
evidence that a larger study and for a longer time is required to further determine the effects of 
Maca in postmenopausal women. 
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Table 1. Body weight, kg and body mass index, [kg/m2] ± SD during the randomized 
crossover design study (n=29). 
 
 
Treatment order Baseline 6 weeks 12 weeks 
Repeated  
measures 
Lambda           P value 
Maca then placebo 
(n= 15) 
57.7 ± 8.4 
[23.2±3.3] 
57.8 ± 8.3 
[23.3 ±3.2] 
58.1 ±8.4 
[23.4 ± 3.3] 
  0.83                   0.29 
 [0.77]                 [0.18] 
Placebo then Maca 
(n=14) 
56.8 ± 8.5 
[22.6 ± 3.2] 
56.6 ±8.6 
[22.5 ± 3.1]  
56.5 ±8.5  
[22.5 ± 3.1] 
  0.84                   0.36 
 [0.88]                 [0.46] 
Data are the mean ± standard deviation (n=29). * Significant difference from baseline (P < 0.05) 
 
 
 
 
TABLE 2. Mean values of serum estradiol, FSH, TSH, SHBG and lipids at baseline,  
following Maca and following placebo. Data are the mean ± SD (n=29).   
 
Baseline 
After 6  
weeks of 
Maca 
After 6  
weeks of 
placebo 
Repeated  
measures 
Lambda      P value 
Weight (kg) 57.3 ±8.3 57.2 ± 8.3 57.4 ± 8.4 0.96              0.54 
BMI (kg/m2) 22.9 ±3.2 22.9 ± 3.1 23.0 ± 3.2 0.96              0.55 
BP Systolic 132.5 ± 18.2 125.6 ± 
19.8* 
126 ± 16.3* 0.80              0.05* 
BP Diastolic 81.8 ± 13.1 73.8± 10.6* 77.7 ± 12.5 0.69              0.01* 
Heart rate 66.5 ± 9.4 68.8 ± 7.8 65.6 ± 6.0 0.81              0.06 
Estradiol (pmol/l) 46.3±8.6 48.3 ±12.5 49.5±18.7 0.93              0.40 
FSH (IU/l) 77.5±19.0 79.9±23.6 75.5±19.7 0.96              0.55 
SHBG (nmol/l) 47.6± 29.5 47.8 ±26.7 48.8 ±35.9 0.99              0.90 
TSH (mIU/L) 1.94±1.4 2.1±1.4 2.0±1.3 0.93              0.40 
Cholesterol (mmol/L) 5.4 ±0.8 5.5±0.9 5.5±0.9 0.98              0.81 
HDL-c (mmol/L) 1.6±0.5 1.64±0.4 1.56±0.4 0.82              0.09 
LDL-c (mmol/L) 3.2±0.8 3.3±0.8 3.3±0.9 0.91              0.32 
TG (mmol/L) 1.4±0.8 1.26±0.56 1.4±0.7 0.92              0.36 
Non-HDL (mmol/L) 3.9±0.8 3.9±0.9 4.1±0.9 0.96              0.64 
Data are the mean ± standard deviation (n=29). BMI, body mass index; BP, blood pressure; FSH, 
follicular-stimulating hormone; HDL, high density lipoprotein; LDL, low density lipoprotein; SHBG, sex 
hormone-binding globulin; TG, triglyceride; TSH, thyroid stimulating hormone. * Significant difference 
from baseline (P < 0.05) 
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TABLE 3. Mean values of scores on the Greene Climacteric Scale at  
baseline, following Maca and following placebo.  
 
Baseline 
After 6  
weeks of 
Maca 
After 6  
weeks of 
placebo 
Repeated  
measures 
Lambda        P value 
Psychological 12.3±5.9 9.3±5.6* 9.0±5.5* 0.68                 0.01*  
Anxiety 6.7±3.5 5.1 ±3.3* 5.0±3.0 * 0.73                 0.02 * 
Depression 5.5 ±3.0 4.2±2.6* 4.0±3.0* 0.69                 0.01* 
Somatic 5.5±3.3 4.7±3.5 4.0±3.2* 0.77                 0.03* 
Vasomotor 2.4±1.4 2.4±1.7 2.6±1.6 0.99                 0.77 
Sexual 
Dysfunction 
1.5±0.9 1.2±1.0 1.2±1.0 0.90                 0.24 
Urinary 2.6±1.4 2.1±1.5 2.0±1.8 0.86                 0.14 
Total score 22.7±9.9 17.6±10.0 
(P = 0.07) 
16.8±9.1* 0.78                 0.04* 
Data are the mean ± standard deviation (n=29). * Significant difference from baseline (P < 0.05) 
 
 
 
TABLE 4. Mean values of scores on the SF 36 V2 Scale at baseline, following  
Maca and following placebo.  
 
Baseline 
After 6  
weeks of 
Maca 
After 6  
weeks of 
placebo 
Repeated  
measures 
Lambda    P value 
Physical Functioning 
(PF) 
49.2 ±5.9 47.1 ±8.1 49.5 ±4.9 0.90               0.25 
Role Physical (RP) 47.6 ±8.2 46.6 ±10.0 48.1± 8.3 0.95               0.50 
Body Pain (BP) 43.1± 9.1 45.8± 8.5 45.5 ±9.1 0.88               0.19 
General Health (GH) 41.7 ±10.3 46.2±7.9* 45.3 ±8.5* 0.74               0.02* 
Vitality (VT) 46.5±11.7 49.7 ±9.7 50.4 ±9.9 0.91               0.26 
Social Functioning (SF)  42.7 ±10.8 47.7± 9.2 
(P = 0.08) 
49.7 ±8.4* 0.62               0.00* 
Role Emotional (RE) 42.8± 11.1 43.5 ±11.5 46.1 ±10.2 0.82               0.07 
Mental Health (MH) 40.6 ±10.7 46.1± 10.8* 
(P = 0.03) 
48.1± 9.1* 
(P=0.003) 
0.68               0.01* 
Physical Component 
Score (PCS) 
48.0 ± 6.7 47.4 ± 6.9 47.7 ± 6.4 0.99               0.86 
Mental Component 
Score (MCS) 
40.9± 11.7 46.2 ±11.6 
(P = 0.06) 
48.3± 10.1* 0.66               0.00* 
Data are the mean ± standard deviation (n=29). * Significant difference from baseline (P < 0.05) 
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TABLE 5. Mean values of scores on the Women’s Health Questionnaire Scale at  
baseline, following Maca and following placebo. 
 
Baseline 
After 6 weeks 
of Maca 
After 6 weeks 
of placebo 
Repeated  
measures 
Lambda         P value 
Depression 0.33 ±0.25 0.21 ±0.20* 0.23± 0.20 0.78                 0.04* 
Somatic 0.47± 0.26 0.41± 0.26 0.31± 0.25* 0.70                 0.01* 
Memory 0.69 ±0.37 0.57 ±0.37 0.60± 0.33 0.87                 0.16 
Vasomotor 0.57± 0.32 0.55±0.43 0.52± 0.39 0.99                 0.87 
Anxiety 0.38 ±0.30  0.18± 0.25* 0.22 ±0.31* 0.63                 0.00* 
Sexual 
Dysfunction 
0.62± 0.40 0.51 ±0.39 0.52 ±0.57 0.93                 0.37 
Sleep 0.53 ±0.36 0.43 ±0.40 0.34 ±0.37* 0.81                0.05* 
Mental 0.24 ±0.34 0.21 ±0.27 0.24 ±0.31 0.99                0.86 
Attention 0.67± 0.36 0.62 ±0.34 0.60 ±0.39 0.92                0.60 
Data are the mean ± standard deviation (n=29). * Significant difference from baseline (P < 0.05) 
 
 
 
 
TABLE 6. Mean values of scores on the Utian Quality of Life Scale  
between Maca and placebo. 
 
After 6 weeks 
of Maca 
After 6 weeks 
of placebo 
Repeated  
measures 
Lambda         P value 
Occupation 22.0 ±5.6 21.4± 6.5 0.99                 0.53 
Health 21.4 ±3.2 21.4±3.3 1.00                 0.97 
Emotion 19.0 ±3.6 19.2± 4.4 1.00                 0.86 
Sexual 8.4 ±2.4 8.7 ±3.1 0.99                 0.55 
Total 70.8±10.2 70.8 ±13.0 1.0                   0.99 
Data are the mean ± standard deviation (n=29). * Significant difference from baseline (P < 0.05) 
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